The drug, costing Rs 1.2 lakh, has been provided by the state government and it is being administered free of cost. Two patients with comorbidity have so far been given the drug and their health is improving. The patients’ health is being closely monitored.
So far, 92 lower-income nations are seeking assistance via the COVAX facility, part of the WHO's ACT Accelerator to boost development of vaccines, therapeutics and diagnostics to combat the pandemic. Some 80 higher-income nations have expressed interest, but many must still confirm their intention to join by the end of this week.
The drug, known as AZD7442, is a combination of two antibodies and is being tested on 48 healthy people aged between 18 and 55, the company said.
So-called convalescent plasma, which has long been used to treat diseases, has emerged as the latest political flashpoint in the race to find therapies for Covid-19. The U.S. FDA on Sunday authorized its use after President Donald Trump blamed the agency for impeding the roll-out of vaccines and therapeutics for political reasons.
The current COVID-19 crisis has highlighted the need for an ample supply of blood plasma. Right now, plasma therapy has been used to treat patients in Maharashtra, Madhya Pradesh and New Delhi. Delhi's health minister Satyendra Jain has also received plasma therapy for COVID-19.
The high court said the BJP-IPFT government's awarding of the supply order to Reliance Life Sciences Pvt Ltd, which does not have requisite documents and experience of supplying life-saving drugs, was "improper".
Novartis Chief Executive Vas Narasimhan said takeover targets in China for global pharmaceuticals groups are scarce due to few novel drugs, data quality fears and lagging regulatory standards in the most-populous country.
New Delhi, May 7 () Pharma major Biocon Tuesday said the company retains economic interest in global commercialisation of Hulio in-licensed by Mylan.
The lives of hundreds of millions of diabetics around the world depend on it and that number is growing rapidly in the developing world as locals adopt Western diets and lead more sedentary lives.
"Serum Institute and IAVI have joined forces in the fight against HIV with the aim of making cost-effective monoclonal antibodies for HIV, and in the fields of antimicrobial resistance and anti-snake venom.
This year at the Eastern Economic Forum in Vladivostok, BIOCAD and Shanghai Pharmaceuticals Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the Peoples Republic of China..
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
